Skip to main content

Table 1 Subjects characteristics at baseline

From: Safety and efficacy of pregabalin in adolescents with fibromyalgia: a randomized, double-blind, placebo-controlled trial and a 6-month open-label extension study

  Double-blind trial Open-label trial (N = 63)
Pregabalin (N = 54) Placebo (N = 53) Total (N = 107)
Hormonal status of female patients, n    
  48 44 92 53
 Premenarchal, n (%) 1 (2.1) 1 (2.3) 2 (2.2) 2 (3.8)
 Menarche, n (%) 47 (97.9) 43 (97.7) 90 (97.8) 51 (96.2)
Age, years     
 Mean (SD) 14.6 (1.2) 14.7 (1.2) 14.7 (1.2) 14.8 (1.4)
 Range 12–17 12–16 12–17 12–17
Age, years, n (%)     
 12 4 (7.4) 3 (5.7) 7 (6.5) 4 (6.3)
 13 5 (9.3) 6 (11.3) 11 (10.3) 8 (12.7)
 14 15 (27.8) 8 (15.1) 23 (21.5) 10 (15.9)
 15 18 (33.3) 21 (39.6) 39 (36.4) 19 (30.2)
 16 10 (18.5) 15 (28.3) 25 (23.4) 16 (25.4)
 17a 2 (3.7) 0 2 (1.9) 6 (9.5)
Race, n (%)     
 White 29 (53.7) 32 (60.4) 61 (57.0) 35 (55.6)
 Asian 21 (38.9) 15 (28.3) 36 (33.6) 20 (31.7)
 Black 2 (3.7) 3 (5.7) 5 (4.7) 4 (6.3)
 Other 2 (3.7) 3 (5.7) 5 (4.7) 4 (6.3)
Weight, kg     
 Mean (SD) 60.4 (21.4) 59.7 (17.7) 60.1 (19.6) 61.6 (18.5)
 Range 28.5–154.7 39.0–127.6 28.5–154.7 29.8–135.5
Height, cm     
 Mean (SD) 160.1 (7.6) 162.3 (8.2) 161.2 (7.9) 161.8 (8.3)
 Range 141.0–177.8 147.0–183.0 141.0–183.0 141.0–184.0
Duration of FM symptoms, years    
 Mean (median) 1.7 (1.1) 2.1 (1.4) 1.9 (1.3) 0.8 (0.5)
 Range 0.3–11.1 0.4–11.7 0.3–11.7 0.33.9
  1. a The study protocol was amended to include subjects aged 17 years after the study had commenced